STOCK TITAN
  1. Home
  2. News
  3. RVNC

Revance Therapeutics Inc - RVNC STOCK NEWS

Welcome to our dedicated news page for Revance Therapeutics (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revance Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revance Therapeutics's position in the market.

News
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) presented two posters at the AAN meeting on DAXXIFY® for cervical dystonia treatment. Data showed customizable retreatment intervals and benefits of DAXXIFY's formulation. The studies suggest long-acting symptom control, low adverse event rates, and potential for tailored treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
-
News
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) grants 222,452 RSUs to 29 new employees, with vesting over four years, subject to continued service. The awards were approved by the Compensation Committee as inducements for employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
News
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) priced an underwritten public offering of 16 million shares of common stock at $6.25 per share, expecting to raise $100 million in gross proceeds. The offering is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
offering
News
Revance Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces a proposed underwritten public offering of $100 million of its common stock, with an option for additional shares. The company plans to utilize the proceeds for commercial growth, product launches, and general corporate purposes. Barclays is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.04%
Tags
offering
-
News
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) reported strong financial results for Q4 and full year 2023, with product revenue reaching $58.5 million and $212.7 million, respectively. The company achieved significant YoY growth of 28% and 80%. The 2024 revenue guidance stands at $280 million, showcasing blockbuster potential in U.S. aesthetics. DAXXIFY for cervical dystonia is on track for a mid-year launch, with positive financial outlook and a focus on achieving positive Adjusted EBITDA in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.15%
Tags
earnings
-
News
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Rhea-AI Summary
Revance Therapeutics (RVNC) to Release Q4 and Full Year 2023 Financial Results on February 28, 2024, with a Conference Call and Webcast to Discuss Results and Corporate Update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
earnings
News
Revance to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) announces participation in upcoming investor conferences with key executives presenting fireside chats. CEO Mark Foley and CFO Tobin Schilke to present at Cowen 44th Annual Healthcare Conference on March 5, 2024, and CEO Mark Foley at Barclays Global Healthcare Conference on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
News
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) has received a permanent J-code for DAXXIFY, a treatment for cervical dystonia, streamlining reimbursement. The pivotal Phase 3 study results published in Neurology reinforce the product's long duration of effect and favorable safety profile. The study showed that DAXXIFY was effective, generally safe, and well-tolerated, with a median duration of effect of over 20 weeks. The U.S. therapeutic neuromodulator market opportunity for DAXXIFY is $2.7 billion, including the over $350 million cervical dystonia market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
-
News
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference on February 7-8, 2024, in New York. CEO Mark J. Foley will be participating in a fireside chat on February 8 at 9:30a.m. EST. The live audio webcast will be available on the company's website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
conferences
News
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) reports a 22% increase in Q4 DAXXIFY® volume sold over Q3, with a projected 2024 product revenue guidance of at least $280 million. Preliminary unaudited Q4 and full year 2023 product revenue for DAXXIFY and RHA® Collection is estimated to be between $58 million and $59 million and $212 million and $213 million, respectively, representing approximately 28% and 80% YoY growth. The company expects to achieve positive Adjusted EBITDA in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
earnings
Stock RVNC logo
Revance Therapeutics Inc

Nasdaq:RVNC

RVNC Rankings

#3161 Ranked by Market Cap
#5006 Ranked by Stock Gains
N/A Ranked by Dividends

RVNC Stock Data

430.41M
70.80M
8.48%
76.13%
13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About RVNC

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form